Company intelligence / Profile preview

Thrive Neuromedical

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Thrive Neuromedical has developed a proprietary, IP-protected device platform ("Dino Egg") that delivers therapeutic sounds—specifically the mother’s recorded voice—to preterm infants in the NICU. The system is designed to improve speech sound differentiation, cognitive outcomes, and overall neurological development. Early studies show positive impact on infant ability to differentiate language from noise and support improved long-term developmental outcomes. The company is pursuing FDA clearance based on Phase I/II SBIR funding and pilot clinical data.

Therapeutic areas: Neurology
Modalities: DeviceDigital therapeutic (IT platform)
Industry: Digital Health Medical Devices

Partnerships

Nationwide Children’s Hospital (research collaboration/spinout)SBIR/STTR program/National Institutes of Health funding partners

Beyond the preview

Go deeper on Thrive Neuromedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thrive Neuromedical.

Explore the full profile